FDA approves first generic Crestor

1 May 2016
drugs_pills_tablets_big

The US Food and Drug Administration on Friday approved the first generic version of Crestor (rosuvastatin calcium), a copy of Anglo-Swedish pharma major AstraZeneca’s (LSE: AZN) blockbuster cholesterol drug that is facing patient expiries.

The generic is approved for the following uses:

  • in combination with diet for the treatment of high triglycerides (hypertriglyceridemia) in adults; and
  • in combination with diet for treatment of patients with primary dysbetalipoproteinemia (Type III hyperlipoproteinemia), a disorder associated with improper breakdown of cholesterol and triglycerides.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Generics